Elutia Inc. (ELUT) stock
ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/301% above fair value
$0.90+0.09 (+11.12%)
Close on Nov 20, 2026Market cap $39.86MP/E –Yield –
Elutia gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Elutia's gross profit for the twelve months ending Jun 30, 2026 was $7.02M, up 18.0% year over year. For fiscal 2025 it was $6.60M, down 1.8% from the year before. The highest annual figure on record is $20.56M in fiscal 2020.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.60M | -1.8% |
| FY2024 | Dec 31, 2024 | $6.72M | -39.2% |
| FY2023 | Dec 31, 2023 | $11.05M | -5.0% |
| FY2022 | Dec 31, 2022 | $11.64M | -38.8% |
| FY2021 | Dec 31, 2021 | $19.02M | -7.5% |
| FY2020 | Dec 31, 2020 | $20.56M | +4.0% |
| FY2019 | Dec 31, 2019 | $19.77M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.45M | -0.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.80M | +30.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.91M | +44.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.85M | +3.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.45M | -48.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.38M | -51.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.32M | -37.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.79M | -37.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.80M | +3.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.84M | -15.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.13M | -56.6% |
| Q3 FY2023 | Sep 30, 2023 | $2.84M | -33.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.71M | -19.9% |
| Q1 FY2023 | Mar 31, 2023 | $3.37M | -8.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.90M | -12.8% |
| Q1 FY2022 | Mar 31, 2022 | $4.28M | -32.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.39M | -43.7% |
| Q3 FY2021 | Sep 30, 2021 | $3.69M | -33.4% |
| Q2 FY2021 | Jun 30, 2021 | $5.61M | +48.4% |
| Q1 FY2021 | Mar 31, 2021 | $6.33M | +21.4% |
| Q4 FY2020 | Dec 31, 2020 | $6.02M | +23.1% |
| Q3 FY2020 | Sep 30, 2020 | $5.54M | -0.0% |
| Q2 FY2020 | Jun 30, 2020 | $3.78M | – |
| Q1 FY2020 | Mar 31, 2020 | $5.22M | – |
| Q4 FY2019 | Dec 31, 2019 | $4.89M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.54M | – |
See a number that looks wrong?